This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Patient-Physician Relationship/ Care  • Treatment Adherence  • Rheumatology  • Osteoporosis  • Drug Therapy  • Adherence  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Bridget M. Kuehn

JAMA. 2005;293:2458.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Washington, DC—The approval of once-monthly ibandronate in March by the Food and Drug Administration (FDA) may substantially improve patients’ ability to adhere to osteoporosis treatments. The trend of drug companies testing osteoporosis drugs in clinical trials that require less frequent doses was highlighted at the Sixth International Symposium on Osteoporosis in April.

The FDA-approved drugs for the treatment of osteoporosis in postmenopausal women include antiresorptive agents that reduce bone loss: estrogen, calcitonin, raloxifene (a selective estrogen receptor modulator or SERM), and bisphosphonates (alendronate, and risedronate, which are taken daily or weekly) and ibandronate (taken monthly). For patients who do not respond to antiresorptives, there is one FDA-approved anabolic agent, teriparatide, a synthetic form of parathyroid hormone, which can help build bone.

Because bisphosphonates are poorly absorbed, they must be taken in the morning on an empty stomach with a full glass of water; patients may not . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?